Gene Transfer of Soluble Transforming Growth Factor Type II Receptor by in Vivo Electroporation Attenuates Lung Injury and Fibrosis

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2006 Oct 5

PMID 17018685

Citations 18

Authors

Mizuho Yamada

Kazuyoshi Kuwano

Takashige Maeyama

Michihiro Yoshimi

Naoki Hamada

Jutaro Fukumoto

Kensuke Egashira

Kenichi Hiasa

Koichi Takayama

Yoichi Nakanishi

Affiliations

Soon will be listed here.

Abstract

Background: Transforming growth factor-beta1 (TGF-beta1) has the potential to induce acute inflammation and apoptosis in lung epithelial cells and plays a central role in subsequent fibrosis.

Aims: To examine a new anti-TGF-beta1 therapy against lung injury and fibrosis, which comprises the transfection of soluble TGF type II receptor (sTGFRII) gene into skeletal muscles by in vivo electroporation.

Methods: Soluble TGFRII was detectable between 1 and 14 days in the serum and significantly increased between 3 and 10 days after gene transfer into muscles. Based on these findings, the sTGFRII gene was injected at 3 days before or 4 days after the bleomycin instillation in order to examine the significance of TGF-beta1 on the early inflammatory phase (day 0 to day 7) or the fibrotic phase (day 7 to day 14) in this model.

Results: Transfection of sTGFRII gene at 3 days before or 4 days after bleomycin instillation significantly attenuated apoptosis, injury, and fibrosis at 7 or 14 days, respectively. This method does not require the use of viral vector or neutralising antibody, and it is therefore possible to avoid problems regarding the pathogenicity of the viral vector or immunocomplex.

Conclusions: This novel anti-TGF-beta1 strategy may have clinical application in the treatment of lung injury and fibrosis.

Citing Articles

Unlocking the protective potential of the angiotensin type 2 receptor (ATR) in acute lung injury and age-related pulmonary dysfunction.

Abadir P, Cosarderelioglu C, Damarla M, Malinina A, Dikeman D, Marx R Biochem Pharmacol. 2023; 220:115978.

PMID: 38081369 PMC: 10880333. DOI: 10.1016/j.bcp.2023.115978.

Immunohistochemical Study of Airways Fibrous Remodeling in Smoking Mice.

Balzano E, De Cunto G, Goracci C, Bartalesi B, Cavarra E, Lungarella G J Histochem Cytochem. 2023; 71(11):577-599.

PMID: 37818941 PMC: 10617442. DOI: 10.1369/00221554231204926.

FAK Inhibition Attenuates Corneal Fibroblast Differentiation In Vitro.

Yeung V, Sriram S, Tran J, Guo X, Hutcheon A, Zieske J Biomolecules. 2021; 11(11).

PMID: 34827680 PMC: 8616004. DOI: 10.3390/biom11111682.

New Insights into Pathomechanisms and Treatment Possibilities for Lung Silicosis.

Adamcakova J, Mokra D Int J Mol Sci. 2021; 22(8).

PMID: 33920534 PMC: 8072896. DOI: 10.3390/ijms22084162.

TGF-β Pathway in Salivary Gland Fibrosis.

Zhang X, Yun J, Han D, In Yook J, Kim H, Cho E Int J Mol Sci. 2020; 21(23).

PMID: 33266300 PMC: 7730716. DOI: 10.3390/ijms21239138.

References

. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161(2 Pt 1):646-64. DOI: 10.1164/ajrccm.161.2.ats3-00. View

Neurohr C, Nishimura S, Sheppard D . Activation of transforming growth factor-beta by the integrin alphavbeta8 delays epithelial wound closure. Am J Respir Cell Mol Biol. 2006; 35(2):252-9. PMC: 2643260. DOI: 10.1165/rcmb.2006-0013OC. View

Kuwano K, Kawasaki M, Maeyama T, Hagimoto N, Nakamura N, Shirakawa K . Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest. 2000; 118(2):451-8. DOI: 10.1378/chest.118.2.451. View

Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Hara N . Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12. Am J Physiol Lung Cell Mol Physiol. 2001; 280(6):L1128-37. DOI: 10.1152/ajplung.2001.280.6.L1128. View

Pittet J, Griffiths M, Geiser T, Kaminski N, Dalton S, Huang X . TGF-beta is a critical mediator of acute lung injury. J Clin Invest. 2001; 107(12):1537-44. PMC: 200192. DOI: 10.1172/JCI11963. View

Hagimoto N, Kuwano K, Inoshima I, Yoshimi M, Nakamura N, Fujita M . TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol. 2002; 168(12):6470-8. DOI: 10.4049/jimmunol.168.12.6470. View

Tsuburai T, Suzuki M, Nagashima Y, Suzuki S, Inoue S, Hasiba T . Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lung prevents bleomycin-induced pulmonary fibrosis via a Fas-Fas ligand-independent pathway. Hum Gene Ther. 2002; 13(16):1945-60. DOI: 10.1089/10430340260355356. View

Selman M, Pardo A . The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003; 29(3 Suppl):S93-7. View

Inoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T . Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2004; 286(5):L1038-44. DOI: 10.1152/ajplung.00167.2003. View

10.

Chandler D, Hyde D, Giri S . Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am J Pathol. 1983; 112(2):170-7. PMC: 1916255. View

11.

Khalil N, Bereznay O, Sporn M, Greenberg A . Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med. 1989; 170(3):727-37. PMC: 2189427. DOI: 10.1084/jem.170.3.727. View

12.

Khalil N, OConnor R, Unruh H, Warren P, Flanders K, Kemp A . Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 1991; 5(2):155-62. DOI: 10.1165/ajrcmb/5.2.155. View

13.

Kulkarni A, Huh C, Becker D, Geiser A, Lyght M, Flanders K . Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993; 90(2):770-4. PMC: 45747. DOI: 10.1073/pnas.90.2.770. View

14.

Spurzem J, Sacco O, Rickard K, Rennard S . Transforming growth factor-beta increases adhesion but not migration of bovine bronchial epithelial cells to matrix proteins. J Lab Clin Med. 1993; 122(1):92-102. View

15.

Khalil N, Whitman C, Zuo L, Danielpour D, Greenberg A . Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest. 1993; 92(4):1812-8. PMC: 288344. DOI: 10.1172/JCI116771. View

16.

Wrana J, Attisano L, Wieser R, Ventura F, Massague J . Mechanism of activation of the TGF-beta receptor. Nature. 1994; 370(6488):341-7. DOI: 10.1038/370341a0. View

17.

Smith R, Strieter R, Zhang K, Phan S, Standiford T, Lukacs N . A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol. 1995; 57(5):782-7. DOI: 10.1002/jlb.57.5.782. View

18.

Sime P, Xing Z, Graham F, Csaky K, Gauldie J . Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997; 100(4):768-76. PMC: 508247. DOI: 10.1172/JCI119590. View

19.

Heldin C, Miyazono K, Ten Dijke P . TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997; 390(6659):465-71. DOI: 10.1038/37284. View

20.

Wang Q, Wang Y, Hyde D, Gotwals P, Koteliansky V, Ryan S . Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax. 1999; 54(9):805-12. PMC: 1745567. DOI: 10.1136/thx.54.9.805. View